AstraZeneca's Stock Advances Amid Market Decline: Key Takeaways for Investors

Astrazeneca (AZN) closed at $188.42, a +2.74% move from the prior day, while the S&P 500 lost 1.67%. The pharmaceutical's upcoming earnings report is expected to show a 0.81% increase in EPS and a 9.02% escalation in revenue compared to the year-ago quarter. The Zacks Rank system predicts a 0.31% rise in the Zacks Consensus EPS estimate, with a current rating of #3 (Hold). The Forward P/E ratio of 17.78 is slightly higher than the industry average, and the PEG ratio of 1.38 is higher than the industry average of 1.52.